Compare Adaptive Biotechnologies Corp (ADPT) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs LyondellBasell Industries NV — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while LyondellBasell Industries NV trades at $55.69 (market cap $17.62B). The key difference: LyondellBasell Industries NV is far larger — about 5.3× Adaptive Biotechnologies Corp's market cap, and LyondellBasell Industries NV pays a 7.55% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | LYB | |
|---|---|---|
Market Cap | $3.33B | $17.62B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $82.38 |
52-Week Low | $10.24 | $42.28 |
Enterprise Value | $3.19B | $29.24B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
LyondellBasell (LYB) trades at $54.61, up 2.33% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$745M in 2025 with revenue declining to $30.15B, though it beat EPS estimates in two of the last three quarters. Recent news highlights a packaging collaboration with Mondelez and upcoming Q2 2026 earnings on July 31. Cash flow remains positive with $61M net inflow in 2025, while debt-to-asset ratio increased to 38.18%.
Outlook is mixed: analyst consensus price target of $73.11 suggests 34% upside, supported by cost-cutting and recycling initiatives, but persistent margin pressures and high debt pose risks. Investors should weigh the value opportunity (P/S of 0.57) against earnings volatility and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
